Key result
Non-viral synthetic nanoparticles offer potential advantages for RNA interference delivery, requiring specific design principles for material selection and synthesis to maximize encapsulation and safety.
Why the study?
The complex natural process of RNA interference and the susceptible nature of oligonucleotides require specific design principles and practical fabrication guidelines for non-viral synthetic nanoparticles.
This review summarizes the design principles, material selection, and synthesis guidelines for non-viral nanoparticles used in RNA interference therapies.
Guides non-viral NP design for RNAi delivery; leaves open clinical translation pending prospective validation.
Ribonucleic acid interference (RNAi) is an innovative treatment strategy for a myriad of indications. Non-viral synthetic nanoparticles (NPs) have drawn extensive attention as vectors for RNAi due to their potential advantages, including improved safety, high delivery efficiency and economic feasibility. However, the complex natural process of RNAi and the susceptible nature of oligonucleotides render the NPs subject to particular design principles and requirements for practical fabrication. Here, we summarize the requirements and obstacles for fabricating non-viral nano-vectors for efficient RNAi. To address the delivery challenges, we discuss practical guidelines for materials selection and NP synthesis in order to maximize RNA encapsulation efficiency and protection against degradation, and to facilitate the cytosolic release of oligonucleotides. The current status of clinical translation of RNAi-based therapies and further perspectives for reducing the potential side effects are also reviewed.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2021) reported a review. Non-viral synthetic nanoparticles for RNA interference was evaluated. Non-viral synthetic nanoparticles offer potential advantages for RNA interference delivery, requiring specific design principles for material selection and synthesis to maximize encapsulation and safety.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: